UMass Medical Joins Group To Boost Drug Development
The University of Massachusetts Medical School has become part of a group that will help the school to develop drug treatments for commercial use, the Worcester-based school announced.
UMass has joined BioPontis Alliance, a hybrid firm based in North Carolina that combines early-stage capital investment with early-stage drug development. The company has already formed agreements with three pharmaceutical companies: Merck, Pfizer and the Janssen Biotech unit of Johnson & Johnson, according to a statement from UMass Medical.
UMass said the collaboration will help the medical school identify innovative breakthroughs that have the potential to become viable treatments for cancer, neurological disorders and other diseases. BioPontis will review and evaluate discoveries from UMass Medical with input from other members within the pharmaceutical industry, the school said. In addition, the alliance will provide direct support for inventors within the UMass faculty.
BioPontis has 10 other universities it calls partners. Among them are: Columbia, New York University, Memorial Sloan Kettering Cancer Center, the University of Pennsylvania, the University of Virginia and the University of North Carolina-Chapel Hill.
WBJ Web Partners
Most Recent
Most Recent
0 Comments